Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 11, 2010, Pages 1800-1805

  Liu, Yan Long ^a   Yang, Yan Mei ^a   Xu, Hui ^a   Dong, Xin Shu ^a  

^a Harbin Medical University   (Switzerland)

Author keywords

B cell specific integration site 1; Cellular homolog of avian myelocytomatosis virus oncogene; Colorectal cancer; Cyclin D2; Ubiquitin specific protease 22

Indexed keywords

BMI1 PROTEIN; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; MYC PROTEIN; PROTEINASE; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

EID: 78149272560     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06352.x     Document Type: Article

References (15)

1. Glinsky GV. Death-from-cancer signatures and contribution of stem cells to metastatic cancer. Cell Cycle 2005; 4: 1171-75.
2. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death from cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 2005; 115: 1503-21.
3. Glinsky GV. Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes. Cell Cycle 2006; 5: 2613-25.
4. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J. Clin. Oncol. 2008; 26: 2846-53.
5. Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006; 5: 1208-16.
6. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, Baek KH. The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr. Patterns 2006; 6: 277-84.
7. Zhao Y, Lang G, Ito S et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol. Cell 2008; 29: 92-10.
8. Zhang XY, Varthi M, Sykes SM et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol. Cell 2008; 29: 102-11.
9. Pijnappel WW, Timmers HT. Dubbing SAGA unveils new epigenetic crosstalk. Mol. Cell 2008; 29: 152-4.
10. Zhang XY, Pfeiffer HK, Thorne AW, McMahon SB. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the Polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 2008; 7: 1522-4.
11. Silva J, García JM, Peña C et al. Implication of Polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin. Cancer Res. 2006; 12: 6929-36.
12. Glinsky GV. Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem. Cell Rev. 2007; 3: 79-93.
13. Berezovska OP. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886-901.
14. Guney I, Wu S, Sedivy JM. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc. Natl. Acad. Sci. USA 2006; 103: 3645-50.
15. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001; 2: 731-7.